AstraZeneca loses appeals court fight over IRA drug price negotiations
AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the Biden-era program.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.